Analysis | Samples | Factors | Units |
---|---|---|---|
Reversed phase NEGATIVE ION MODE | 19_A6_AT2 | Genotype:Drug Resistant | Treatment:Atovaquone | Peak intensity |
Reversed phase NEGATIVE ION MODE | 28_A6_AT3 | Genotype:Drug Resistant | Treatment:Atovaquone | Peak intensity |
Reversed phase NEGATIVE ION MODE | 9_A6_AT1 | Genotype:Drug Resistant | Treatment:Atovaquone | Peak intensity |
Reversed phase NEGATIVE ION MODE | 21_A6_CT2 | Genotype:Drug Resistant | Treatment:Control | Peak intensity |
Reversed phase NEGATIVE ION MODE | 31_A6_CT3 | Genotype:Drug Resistant | Treatment:Control | Peak intensity |
Reversed phase NEGATIVE ION MODE | 7_A6_CT1 | Genotype:Drug Resistant | Treatment:Control | Peak intensity |
Reversed phase NEGATIVE ION MODE | 17_D6_DT2 | Genotype:Drug Resistant | Treatment:DSM-1 | Peak intensity |
Reversed phase NEGATIVE ION MODE | 20_A6_DT2 | Genotype:Drug Resistant | Treatment:DSM-1 | Peak intensity |
Reversed phase NEGATIVE ION MODE | 26_A6_DT3 | Genotype:Drug Resistant | Treatment:DSM-1 | Peak intensity |
Reversed phase NEGATIVE ION MODE | 8_A6_DT1 | Genotype:Drug Resistant | Treatment:DSM-1 | Peak intensity |
Reversed phase NEGATIVE ION MODE | 12_D6_AT1 | Genotype:Wild-type | Treatment:Atovaquone | Peak intensity |
Reversed phase NEGATIVE ION MODE | 16_D6_AT2 | Genotype:Wild-type | Treatment:Atovaquone | Peak intensity |
Reversed phase NEGATIVE ION MODE | 25_D6_AT3 | Genotype:Wild-type | Treatment:Atovaquone | Peak intensity |
Reversed phase NEGATIVE ION MODE | 10_D6_CT1 | Genotype:Wild-type | Treatment:Control | Peak intensity |
Reversed phase NEGATIVE ION MODE | 18_D6_CT2 | Genotype:Wild-type | Treatment:Control | Peak intensity |
Reversed phase NEGATIVE ION MODE | 29_D6_CT3 | Genotype:Wild-type | Treatment:Control | Peak intensity |
Reversed phase NEGATIVE ION MODE | 11_D6_DT1 | Genotype:Wild-type | Treatment:DSM-1 | Peak intensity |